Today: 10 June 2026
Rocket Lab stock slides again; RKLB ends down 9% as investors eye earnings and Washington risk
6 February 2026
1 min read

Rocket Lab stock slides again; RKLB ends down 9% as investors eye earnings and Washington risk

New York, Feb 5, 2026, 21:26 EST — Market closed

  • Rocket Lab shares dropped 9.3% to close at $66.32, slipping roughly 6% more in after-hours trading.
  • The decline marked the end of two sharp sell-offs following a short-lived rally earlier in the week fueled by SpaceX-xAI news.
  • Rocket Lab’s earnings and conference call on Feb. 26 mark the next key date for investors.

Shares of Rocket Lab Corp plunged 9.29% Thursday, ending the day at $66.32 and adding to a tough stretch for the small-launch and space-systems firm. After-hours trading saw the stock dip another 6%.

Rocket Lab has dropped about 18% since Tuesday’s close, sliding after two steep sell-offs that came after an initial rally. Traders are using the stock as a sort of high-volatility gauge for risk appetite in space-related companies, where sparse news can trigger quick price swings.

The stock dropped amid a widespread selloff in U.S. growth shares Thursday, with the Nasdaq tumbling 1.6% and the S&P 500 falling 1.2%, the Associated Press reported.

Rocket Lab climbed 3.9% on Tuesday following Elon Musk’s announcement of a SpaceX and xAI merger, pegging the combined company’s value at $1.25 trillion and boosting a group of space stocks. “Others may buy into Musk’s grand vision of data centers in the cosmos,” said AJ Bell investment director Russ Mould. Seraphim Space CEO Mark Boggett called it “the strongest validation yet that space will be the backbone of the next wave of AI.” Reuters

Shares came under continued pressure after Congress refused to allocate funds for NASA’s Mars Sample Return mission, a project Rocket Lab had positioned as a commercial solution. This move forced investors to rethink the growth potential baked into the stock’s valuation.

Rocket Lab, headquartered in Long Beach, California, offers launch services and space hardware, operating its Electron rocket while developing the larger Neutron vehicle. The company plans to release its fourth-quarter and full-year 2025 results after the U.S. market closes on Feb. 26, followed by a conference call at 5 p.m. Eastern.

The Feb. 26 report will be the next major trigger for the stock, with investors eager for updates on demand, margins, and timelines. They’ll also watch closely for any shifts in tone, especially after a week dominated more by outside headlines than by any new Rocket Lab announcements.

That said, the setup works both ways. A disappointing update on 2026 forecasts or further delays in hitting development targets could weigh on a stock known for momentum trading—especially if the wider market remains cautious.

Traders will be eyeing if Thursday’s late slide spills over into Friday, and if the stock can steady itself before the Feb. 26 earnings report.

Stock Market Today

  • Palantir Technologies (PLTR) Shares Seen Fairly Valued Amid Recent Decline
    June 10, 2026, 5:48 PM EDT. Palantir Technologies has seen its share price fall 13.2% over the past week and 21.3% year to date, following extraordinary gains in prior years. At $132.07 per share, Palantir trades slightly below its estimated intrinsic value of $145.11 based on a Discounted Cash Flow (DCF) analysis, suggesting a modest 9% discount. The company posted $2.69 billion in free cash flow over the past twelve months, with projections rising to $16.11 billion by 2030. Despite recent volatility tied to sentiment on artificial intelligence and software spending, Palantir remains fairly valued but not a clear bargain. Investors should monitor further market developments and valuation metrics to gauge future opportunities or risks.

Latest articles

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

Parabilis Medicines (PBLS) soars 58% after $670 million IPO beats range

10 June 2026
Parabilis Medicines soared 58% above its $20 IPO price to close at $31.60 in its Nasdaq debut after raising a record $670 million, reflecting strong investor demand for its Helicon drug platform ahead of a pivotal Phase 3 desmoid tumor trial planned for 2027; Regeneron’s $75 million private placement added credibility.
Joby Aviation Shares Slip After CFO Files to Sell Stock

Joby Aviation Shares Slip After CFO Files to Sell Stock

10 June 2026
Joby Aviation fell 4.47% to $8.86 after CFO Rodrigo Brumana disclosed selling 78,489 shares under a prearranged 10b5-1 plan, with no new certification or commercial-launch updates, leaving investors focused on regulatory progress and cash burn as the key catalysts for the stock.
YY Group Shares Spike as Humanoid Robot Plans Unveiled

YY Group Shares Spike as Humanoid Robot Plans Unveiled

10 June 2026
YY Group Holding shares surged to $0.165 on heavy volume after announcing a commercial humanoid-robotics initiative using Unitree G1 robots and facility-management data, reframing the company as a robotics-and-AI data play; the rally comes despite 2025 net loss, dilution risk from a relaunched at-the-market share-sale program, and no disclosed robot-related revenue or contracts.
Super Micro (SMCI) stock slides 9% after earnings spike — what to watch before Friday’s trade
Previous Story

Super Micro (SMCI) stock slides 9% after earnings spike — what to watch before Friday’s trade

Ford stock slips before market open as EV sales dive and Geely talks linger
Next Story

Ford stock slips before market open as EV sales dive and Geely talks linger

Go toTop